Loading
A phase 1 trial of NST-628 run by Nested Therapeutics, Inc, now recruiting.
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors is a phase 1 interventional study registered as NCT06326411 by Nested Therapeutics, Inc, with 230 participants planned, started 2024-04-09. Conditions recorded: Oncology, MEK Mutation, RAF Gene Mutation, Ras (KRAS or NRAS) Gene Mutation, Melanoma, NSCLC, Glioma, Solid Tumor, Adult and MAPK Pathway Gene Mutation. Interventions recorded: NST-628.
Shares NST-628, Nested Therapeutics, Brain and spinal cord tumours (all types), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Melanoma, Metastatic cancer (cancer that has spread), Non-small-cell lung cancer and the tag pipeline.
Shares Brain and spinal cord tumours (all types), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Brain and spinal cord tumours (all types), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Melanoma, Non-small-cell lung cancer and the tag pipeline.
Shares Melanoma, Metastatic cancer (cancer that has spread), Non-small-cell lung cancer and the tag pipeline.
Shares Melanoma, Non-small-cell lung cancer and the tag pipeline.
Shares Melanoma, Metastatic cancer (cancer that has spread), Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/